Free Trial

Sangamo Therapeutics (SGMO) Insider Trading & Ownership

Sangamo Therapeutics logo
$2.47 +0.16 (+6.93%)
(As of 12/20/2024 05:40 PM ET)

Sangamo Therapeutics (NASDAQ:SGMO) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
2.80%
Number Of
Insiders Buying
(Last 3 Years)
1
Amount Of
Insider Buying
(Last 3 Years)
$25,032.96
Number Of
Insiders Selling
(Last 3 Years)
1
Amount Of
Insider Selling
(Last 3 Years)
$5.83 M
Get SGMO Insider Trade Alerts

Want to know when executives and insiders are buying or selling Sangamo Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

SGMO Insider Buying and Selling by Quarter

Sangamo Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/26/2023Biogen Inc.Major ShareholderSell6,000,000$0.50$3,000,000.00  
8/29/2022Biogen Inc.Major ShareholderSell400,000$5.33$2,132,000.00  
6/3/2022John MarkelsDirectorBuy6,784$3.69$25,032.96  
12/27/2021Biogen Inc.Major ShareholderSell600$8.56$5,136.00  
12/23/2021Biogen Inc.Major ShareholderSell81,187$8.55$694,148.85  
(Data available from 1/1/2013 forward)

SGMO Insider Trading Activity - Frequently Asked Questions

The list of insiders at Sangamo Therapeutics includes Biogen Inc., and John Markels. Learn more on insiders at SGMO.

2.80% of Sangamo Therapeutics stock is owned by insiders. Learn more on SGMO's insider holdings.

The following insider sold SGMO shares in the last 24 months: Biogen Inc. ($3,000,000.00).

Insiders have sold a total of 6,000,000 Sangamo Therapeutics shares in the last 24 months for a total of $3,000,000.00 sold.

Sangamo Therapeutics Key Executives

  • Dr. Alexander D. Macrae Ch.B (Age 61)
    M.B., MRCP, Ph.D., CEO, President & Director
    Compensation: $722.67k
  • Dr. Nathalie Dubois-Stringfellow Ph.D. (Age 62)
    Senior VP & Chief Development Officer
    Compensation: $459.9k
  • Ms. Amy Pooler Ph.D.
    Head of Research
  • Mr. Gregory Davis Ph.D.
    Head of Technology
  • Ms. Aron Feingold
    Head of Corporate Communications & Investor Relations Officer
  • Mr. Scott B. Willoughby (Age 49)
    Senior VP, General Counsel & Corporate Secretary
  • Phillip Ramsey
    Head of Technical Operations
  • Ms. Stephanie J. Seiler CLP
    Head of Business Development & Alliance Management
  • Mr. David Ojala
    Scientist II - Discovery & Translational Research
  • Louise Wilkie
    Vice President of Investor Relations & Corporate Communications


This page (NASDAQ:SGMO) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners